title: Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma.
abstract: BACKGROUND
  Overexpression of decoy receptor 3 (DcR3) have been reported in various classes of malignancies. However, its expression and clinicopathological contribution in gliomas has not been fully elucidated.
  
  
  OBJECTIVE
  To explore the expression and clinical significance of DcR3 protein in relation to tumor cell differentiation and proliferation in glioma cell lines and tissues.
  
  
  METHODS
  One hundred and twenty-five samples of glioma patients and 18 cases of normal brain tissues were recruited. The expression of DcR3 protein was detected using immunohistochemistry. Tumor differentiation was assessed by histologic characters and the status of glial fibrillary acidic protein (GFAP). Tumor cell labeling indexes (LIs) of Ki-67 and PCNA were also obtained. The relationship between the DcR3 level and clinicopathological features was investigated, including tumor differentiation, LIs, and survival. Meanwhile, the expression of DcR3 protein was also measured in the supernatants of 8 glioma cell lines and glioma cells freshly prepared from 8 human glioblastoma specimens by using western blot.
  
  
  RESULTS
  The level of DcR3 protein in gliomas was significantly higher than that in normal brain tissues (P < 0.01). DcR3 expression showed positive correlations with tumor pathological grade (r = 0.621, P < 0.01) and negative with GFAP expression (r = -0.489, P < 0.01). Furthermore, there were positive correlations between DcR3 expression and Ki-67, PCNA LIs (r = 0.529, P < 0.01; r = 0.556, P < 0.01). The survival in the DcR3 negative group was 50 ± 1.79 months, longer than that of the DcR3 positive group (48.36 ± 2.90), however, without significance (P = 0.149). Different levels of DcR3 could also be detected in the culturing supernatants of all the 8 glioma cell lines and glioma cells freshly obtained from 8 human glioblastoma specimens.
  
  
  CONCLUSIONS
  The overexpression of DcR3 might play a crucial role in the tumorigenesis, differentiation, and proliferation of glioma.
authors.affiliation: Departments of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, Guangdong 510515, China ; Department of Radiology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, China.
authors.forename: Suning
authors.initials: S
authors.lastname: Huang
authors.affiliation: Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, China.
authors.forename: Gang
authors.identifier: 0000-0002-4864-1451
authors.initials: G
authors.lastname: Chen
authors.affiliation: Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, China.
authors.forename: Yiwu
authors.initials: Y
authors.lastname: Dang
authors.affiliation: Departments of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, Guangdong 510515, China.
authors.forename: Long-Hua
authors.initials: LH
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D016022:Case-Control Studies; D049109:Cell Proliferation; D005260:Female; D015870:Gene Expression; D005910:Glioma / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D053323:Receptors, Tumor Necrosis Factor, Member 6b / Q000235:genetics* / Q000378:metabolism; D055815:Young Adult
chemical_list: D019394:Ki-67 Antigen; D018809:Proliferating Cell Nuclear Antigen; D053323:Receptors, Tumor Necrosis Factor, Member 6b; C505911:TNFRSF6B protein, human
references.citation: J Exp Ther Oncol. 2011;9(2):109-18
references.pmid: 21699018
references.citation: BMC Cancer. 2012 May 14;12:176
references.pmid: 22583667
references.citation: PLoS One. 2013;8(3):e60317
references.pmid: 23555954
references.citation: Kaohsiung J Med Sci. 2004 Mar;20(3):124-7
references.pmid: 15124896
references.citation: Asian Pac J Cancer Prev. 2012;13(2):719-24
references.pmid: 22524850
references.citation: Ups J Med Sci. 2010 Nov;115(4):232-7
references.pmid: 20977315
references.citation: Acta Neuropathol. 2005 Mar;109(3):294-8
references.pmid: 15627206
references.citation: Int J Clin Exp Med. 2013 Sep 01;6(8):700-5
references.pmid: 24040480
references.citation: PLoS One. 2013 Apr 10;8(4):e61054
references.pmid: 23593387
references.citation: Natl Med J India. 2008 Nov-Dec;21(6):275-8
references.pmid: 19691215
references.citation: Cancer Res. 2001 Mar 15;61(6):2759-65
references.pmid: 11289159
references.citation: Pathol Res Pract. 2010 Sep 15;206(9):631-41
references.pmid: 20591579
references.citation: Ups J Med Sci. 2008;113(3):297-304
references.pmid: 18991242
references.citation: Biomarkers. 2011 Mar;16(2):155-60
references.pmid: 21155709
references.citation: Biochem Biophys Res Commun. 2010 Mar 19;393(4):888-93
references.pmid: 20175993
references.citation: PLoS One. 2013 Oct 25;8(10):e74272
references.pmid: 24204567
references.citation: BMC Immunol. 2012 Jun 06;13:28
references.pmid: 22672288
references.citation: BMC Cancer. 2013 Jan 16;13:21
references.pmid: 23320393
references.citation: PLoS One. 2013;8(3):e59708
references.pmid: 23527257